Biomarin Pharmaceutical Inc. (BMRN)
BioMarin Targets Faster Deleveraging as Amicus Deal Expands Rare-Disease Growth
BioMarin Pharmaceutical NASDAQ: BMRN outlined its growth strategy, integration plans for Amicus Therapeutics and pipeline priorities during a Canaccord discussion with Chief Financial Officer Brian Mueller.
BMRN Stock Up as Q2 Earnings Beat on Sales Growth, 2026 Outlook Raised
BioMarin stock rises on Q2 sales beat and raises 2026 outlook, highlighting strong Voxzogo growth, Amicus additions and momentum in key therapies.
BioMarin Pharmaceutical Inc. (BMRN) Q2 2026 Earnings Call Transcript
BioMarin Pharmaceutical Inc. (BMRN) Q2 2026 Earnings Call Transcript
Compared to Estimates, BioMarin (BMRN) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for BioMarin (BMRN) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
BioMarin Pharmaceutical Q2 Earnings Call Highlights
BioMarin Pharmaceutical NASDAQ: BMRN reported second-quarter 2026 revenue of nearly $1 billion, up 20% from a year earlier, as growth across its rare-disease portfolio and the recently completed Amicus acquisition supported results. The company raised its full-year revenue, VOXZOGO revenue and non-GAAP diluted earnings-per-share guidance, though it did not provide updated ranges during the call.
BioMarin Pharmaceutical (BMRN) Surpasses Q2 Earnings and Revenue Estimates
BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $1.2 per share, beating the Zacks Consensus Estimate of $0.96 per share. This compares to earnings of $1.44 per share a year ago.
Analysts Estimate BioMarin Pharmaceutical (BMRN) to Report a Decline in Earnings: What to Look Out for
BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioMarin: Commercial Infrastructure Is The Hidden Growth Asset
BioMarin: Commercial Infrastructure Is The Hidden Growth Asset
FDA Accepts BMRN's sNDA Seeking Full Approval for Voxzogo
BioMarin's FDA filing for full Voxzogo approval in achondroplasia has been accepted, with a regulatory decision expected by Feb. 28, 2027.
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
BioMarin (BMRN) Up 0.2% Since Last Earnings Report: Can It Continue?
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock?
BioMarin's Voxzogo Meets Goal in Late-Stage Study for Hypochondroplasia
BMRN's shares rise after Voxzogo hits the main goal in a late-stage hypochondroplasia study, supporting planned FDA filings in 2026.
